report-image

Chidamide Market Analysis By Type (5 mg, Others); Application (PECL Treatment, Other Cancers Treatment) & Forecast 2024-2035

  • PUBLISHED ON
  • 4/6/2023
  • NO OF PAGES
  • 267
  • CATEGORY
  • Healthcare & Life Sciences
Overview
Chidamide is a type of cancer drug that belongs to the class of histone deacetylase (HDAC) inhibitors. It is used in the treatment of peripheral T-cell lymphoma (PTCL), a rare form of non-Hodgkin's lymphoma that affects the white blood cells. Chidamide works by blocking the activity of HDAC enzymes, which are involved in regulating gene expression and cellular differentiation. The global chidamide market is expected to grow at a significant rate over the coming years due to the increasing incidence of PTCL and the growing demand for targeted cancer therapies.
The Asia-Pacific region is expected to be the fastest-growing market for chidamide, owing to the high prevalence of PTCL in the region and the growing demand for effective cancer therapies. China is the largest market for chidamide in the Asia-Pacific region, accounting for over 50% of the total market share.
Some of the key players in the chidamide market include Chipscreen Biosciences Ltd., PharmaEssentia Corporation, Suzhou Zelgen Biopharmaceuticals Co., Ltd., and CSPC ZhongQi Pharmaceutical Technology Co., Ltd. These companies are focusing on developing new formulations and expanding their market presence to gain a competitive advantage in the market.
Segment Overview
Chidamide is a type of histone deacetylase (HDAC) inhibitor used in the treatment of cancer. It works by inhibiting the activity of HDAC enzymes, which play a role in the regulation of gene expression. As a result, chidamide can help to slow or stop the growth of cancer cells.
In terms of market segments, the chidamide market can be divided based on various factors such as indication, route of administration, and geography.
Indication: Chidamide is primarily used in the treatment of two types of cancer: peripheral T-cell lymphoma (PTCL) and relapsed or refractory multiple myeloma. Therefore, the market segment for chidamide would primarily consist of patients suffering from these conditions.
Route of Administration: Chidamide can be administered orally or intravenously, depending on the condition being treated. Therefore, the market segment for chidamide could be further segmented based on the route of administration.
Geography: The market for chidamide could also be segmented based on geography, as the drug may be available in certain regions but not in others. For example, chidamide is currently only approved for use in China, and therefore the market segment for chidamide would be limited to this region.
Overall, the market for chidamide is relatively small, given its limited approval and use in only a few specific indications. However, as more research is conducted on its efficacy and safety, the market segment for chidamide may expand in the future.
Geographical Overview
Chidamide is a drug that belongs to the class of histone deacetylase (HDAC) inhibitors and is used in the treatment of various types of cancer. The market for chidamide is primarily concentrated in the Asia-Pacific region, particularly in China, where the drug is manufactured and marketed under the brand name "Epidaza."
China has the largest market for chidamide due to the large patient population, increasing prevalence of cancer, and the availability of cost-effective treatment options. The drug has also received regulatory approval in other countries such as South Korea and the Philippines, which have contributed to the growth of the chidamide market in the Asia-Pacific region.
The market for chidamide is also expanding in other regions, such as Europe and North America, where the drug is undergoing clinical trials and is expected to receive regulatory approval in the coming years. However, the market in these regions is expected to be smaller compared to the Asia-Pacific region due to the availability of other HDAC inhibitors and higher healthcare costs.
In summary, the chidamide market is currently concentrated in the Asia-Pacific region, particularly in China, and is expected to expand globally in the future.
COVID Impact
Chidamide is a type of histone deacetylase (HDAC) inhibitor drug used in the treatment of peripheral T-cell lymphoma. The COVID-19 pandemic has had a mixed impact on the chidamide market.
On the one hand, the pandemic has disrupted supply chains and manufacturing operations, leading to temporary shortages of certain drugs, including chidamide. Additionally, the pandemic has diverted resources and attention away from other medical conditions, leading to reduced demand for certain drugs, including chidamide.
On the other hand, the COVID-19 pandemic has led to an increased awareness of the importance of healthcare and medical research, which could lead to increased funding and support for the development and distribution of drugs like chidamide.
Overall, the impact of the COVID-19 pandemic on the chidamide market is complex and multifaceted, and will likely continue to evolve as the pandemic situation changes.
Competitive Analysis
Chidamide is a histone deacetylase inhibitor used in the treatment of peripheral T-cell lymphoma. The market for Chidamide is highly competitive, with several companies vying for a share of the market.
The major players in the Chidamide market are Jiangsu Hengrui Medicine, Mundipharma, and Chipscreen Biosciences. Jiangsu Hengrui Medicine is the leading player in the Chidamide market, with a large share of the market due to its extensive product portfolio and strong distribution network.
Mundipharma is also a major player in the Chidamide market, with a strong presence in Europe and Asia. The company has been actively expanding its product portfolio through collaborations and partnerships with other pharmaceutical companies.
Chipscreen Biosciences is a China-based biopharmaceutical company that specializes in the development of small molecule drugs. The company's Chidamide product, Epidaza, was the first HDAC inhibitor approved for the treatment of peripheral T-cell lymphoma in China.
Other players in the Chidamide market include Chiome Bioscience, Sumitomo Dainippon Pharma, and Zhejiang Hisun Pharma. These companies have also been actively expanding their product portfolios and exploring new markets to gain a larger share of the Chidamide market.
Overall, the Chidamide market is highly competitive, with several players vying for a share of the market. The key players in the market have been focusing on product development and expanding their distribution networks to gain a competitive edge. As the demand for Chidamide continues to grow, the market is expected to become even more competitive in the coming years.
Base Year: 2023
Historic Year: 2016-2022
Forecast: 2024-2035

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process




We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).

Solution

The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.


Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


Conclusion

The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.

CHOOSE LICENSE TYPE
QLOUD
Pricing

Select a license type that suits your business needs

Single User Access

US $4250

Only Four Thousand Two Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $5250

Only Five Thousand Two Hundred Fifty US dollar

  • 5 Users access
  • 25% Additional Free Customization
  • Access Report summaries for Free
  • Guaranteed service
  • Dedicated Account Manager
  • Discount of 20% on next purchase
  • Get personalized market brief from Lead Author
  • Printing of Report permitted
  • Discount of 20% on next purchase
  • 100% Service Guarantee until achievement of ROI
Enterprise User Cost

US $6250

Only Six Thousand Two Hundred Fifty US dollar

  • Unlimited User Access
  • 30% Additional Free Customization
  • Exclusive Previews to latest or upcoming reports
  • Discount of 30% on next purchase
  • 100% Service Guarantee until achievement of ROI